ERBB2 and ductal breast carcinoma in situ: A future study with paired DCIS and invasive ductal carcinoma (IDC) will determine whether the multiple HER2-amplified DCIS clones will all be selected during invasion as shown in the “multiclonal invasion” model [9] or only the last clone be selected as suggested by the “clone selection” model [41].